FBRX
NASDAQ HealthcareForte Biosciences, Inc. - Common Stock
Biotechnology
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as celiac disease, vitiligo, alopecia areata, and type 1 diabetes. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
๐ Market Data
| Price | $44.99 |
|---|---|
| Volume | 785,061 |
| Market Cap | 921.34M |
| Beta | 2.840 |
| RSI (14-Day) | 89.3 Overbought |
| 200-Day MA | $23.71 |
| 50-Day MA | $23.14 |
| 52-Week High | $46.41 |
| 52-Week Low | $9.10 |
| Forward P/E | -10.86 |
| Price / Book | 19.10 |
๐ฏ Investment Strategy Scores
FBRX scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Over-Hyped (99/100) โ this strategy Overbought stocks (potential short candidates).
Lowest fit among scored strategies: ๐ฐ Dividend Daddy (2/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find FBRX in your text
Paste any article, transcript, or post โ the tool will extract FBRX and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-07-16.